Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
-
11901
-
11902
<i>CBP/p300-Interacting Transactivator with Glu/Asp-Rich C-Terminal Domain 2</i> (CITED2) regulates GATA-2 expression in K562 cells.
Published 2015“…Actin was used as a loading control. (B,C) <i>GATA-2</i> mRNA expression and <i>GATA-2</i> 1S and 1G transcripts were significantly decreased (mean ± SE, n = 3, p < 0.001). * p<0.05.…”
-
11903
-
11904
-
11905
-
11906
<i>C. trachomatis</i> L2 induces a biphasic activation of Erk1/2 which contributes to the induction of <i>fgf2</i> mRNA expression.
Published 2011“…Inhibition of either the early peak of Erk activation or the late peak of Erk activation decreased <i>C. trachomatis</i> L2 induction of <i>fgf2</i> mRNA but did not affect the distribution of FGF2 isoforms. …”
-
11907
Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase
Published 2015“…Importantly, a remarkable effect is also observed in treatments with the anticancer compound cytarabine (AraC), for which a 10,000 fold decrease in IC50 occurred. …”
-
11908
-
11909
-
11910
-
11911
-
11912
-
11913
-
11914
The recruitment of Paf1C to the <i>frq</i> ORF is regulated by the WCC activity.
Published 2025“…<p>(A) The enrichment of PAF-1 (Left) or RTF-1 (Right) at the <i>frq</i> ORF middle region significantly decreased in <i>wc-2</i><sup><i>KO</i></sup> strain at DD14. …”
-
11915
-
11916
Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
11917
Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
11918
Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
11919
-
11920